Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM

IF 9.3 1区 医学 Q1 CLINICAL NEUROLOGY
Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Barbara C. Jones, Sebastian Stark, Gnana Prakash Balasubramanian, Christopher Previti, Robert J. Autry, Petra Fiesel, Felix Sahm, David Reuss, Andreas von Deimling, Cornelis M. van Tilburg, Kristian W. Pajtler, Till Milde, Uta Dirksen, Christof M. Kramm, André O. von Bueren, Caroline Hutter, Bram de Wilde, Jan Molenaar, Nicolas U. Gerber, Olli Lohi, Monica C. Munthe-Kaas, Kleopatra Georgantzi, Bernarda Kazanowska, Michal Zápotocký, Antonis Kattamis, Maria Filippidou, Iris Fried, Stefan M. Pfister, Olaf Witt, David T. W. Jones
{"title":"Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM","authors":"Elke Pfaff,&nbsp;Kathrin Schramm,&nbsp;Mirjam Blattner-Johnson,&nbsp;Barbara C. Jones,&nbsp;Sebastian Stark,&nbsp;Gnana Prakash Balasubramanian,&nbsp;Christopher Previti,&nbsp;Robert J. Autry,&nbsp;Petra Fiesel,&nbsp;Felix Sahm,&nbsp;David Reuss,&nbsp;Andreas von Deimling,&nbsp;Cornelis M. van Tilburg,&nbsp;Kristian W. Pajtler,&nbsp;Till Milde,&nbsp;Uta Dirksen,&nbsp;Christof M. Kramm,&nbsp;André O. von Bueren,&nbsp;Caroline Hutter,&nbsp;Bram de Wilde,&nbsp;Jan Molenaar,&nbsp;Nicolas U. Gerber,&nbsp;Olli Lohi,&nbsp;Monica C. Munthe-Kaas,&nbsp;Kleopatra Georgantzi,&nbsp;Bernarda Kazanowska,&nbsp;Michal Zápotocký,&nbsp;Antonis Kattamis,&nbsp;Maria Filippidou,&nbsp;Iris Fried,&nbsp;Stefan M. Pfister,&nbsp;Olaf Witt,&nbsp;David T. W. Jones","doi":"10.1007/s00401-025-02945-9","DOIUrl":null,"url":null,"abstract":"<div><p>Diffuse midline glioma (DMG; a subtype of pediatric high-grade glioma) is a fatal disease in children, due to the localization in critical structures of the central nervous system, its invasive nature, and limited treatment options. Molecularly, DMG with loss of histone 3 K27 trimethylation (mostly through the typical K27M-mutation in histone 3) have been relatively well characterized, however, no unambiguous Achilles’ heel for targeted therapeutic approaches could be identified to date. This study integrates detailed molecular characteristics of pediatric DMGs with clinical data in a large, international cohort in order to contribute to a better understanding necessary for further development of therapeutic approaches. A total of 162 DMG tumors were analyzed within the INFORM registry from 01/2015 to 11/2023 using comprehensive molecular profiling (including exome, whole-genome and RNA next-generation sequencing approaches, complemented with DNA methylation analysis). Molecular results were correlated with clinical data of the respective patients including the treatment regimen applied and patients’ outcomes. This well-defined cohort of histone 3 K27-altered DMG according to the current WHO classification showed typical molecular alterations for this entity, with differences in frequencies in specific subgroups. The presence of <i>TP53</i> mutation and the absence of MAPK pathway alteration in the tumors were associated with worse outcomes. In a substantial proportion of patients, genetic alterations serving as targets for potential therapeutic approaches could be identified. This large, international, prospective DMG cohort combines comprehensive molecular characterization of the tumors with registry-level clinical data, thereby contributing to a better understanding of the underlying tumor biology, potential prognostic and predictive markers and the potential impact of targeted therapies.</p></div>","PeriodicalId":7012,"journal":{"name":"Acta Neuropathologica","volume":"150 1","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00401-025-02945-9.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropathologica","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00401-025-02945-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Diffuse midline glioma (DMG; a subtype of pediatric high-grade glioma) is a fatal disease in children, due to the localization in critical structures of the central nervous system, its invasive nature, and limited treatment options. Molecularly, DMG with loss of histone 3 K27 trimethylation (mostly through the typical K27M-mutation in histone 3) have been relatively well characterized, however, no unambiguous Achilles’ heel for targeted therapeutic approaches could be identified to date. This study integrates detailed molecular characteristics of pediatric DMGs with clinical data in a large, international cohort in order to contribute to a better understanding necessary for further development of therapeutic approaches. A total of 162 DMG tumors were analyzed within the INFORM registry from 01/2015 to 11/2023 using comprehensive molecular profiling (including exome, whole-genome and RNA next-generation sequencing approaches, complemented with DNA methylation analysis). Molecular results were correlated with clinical data of the respective patients including the treatment regimen applied and patients’ outcomes. This well-defined cohort of histone 3 K27-altered DMG according to the current WHO classification showed typical molecular alterations for this entity, with differences in frequencies in specific subgroups. The presence of TP53 mutation and the absence of MAPK pathway alteration in the tumors were associated with worse outcomes. In a substantial proportion of patients, genetic alterations serving as targets for potential therapeutic approaches could be identified. This large, international, prospective DMG cohort combines comprehensive molecular characterization of the tumors with registry-level clinical data, thereby contributing to a better understanding of the underlying tumor biology, potential prognostic and predictive markers and the potential impact of targeted therapies.

弥漫性中线胶质瘤的分子特征和临床特征在儿科精准肿瘤学注册中心INFORM。
弥漫性中线胶质瘤(DMG,小儿高级胶质瘤的一种亚型)是一种致命的儿童疾病,由于其定位于中枢神经系统的关键结构,其侵袭性和有限的治疗选择。从分子上讲,组蛋白3k27三甲基化缺失的DMG(主要是通过组蛋白3中典型的k27m突变)已经得到了相对较好的表征,然而,迄今为止,还没有明确的靶向治疗方法的致命弱点。本研究将儿童dmg的详细分子特征与大型国际队列的临床数据相结合,以便更好地了解进一步开发治疗方法所必需的知识。在2015年1月至2023年11月期间,通过综合分子分析(包括外显子组、全基因组和RNA新一代测序方法,并辅以DNA甲基化分析),在INFORM登记处共分析了162例DMG肿瘤。分子结果与患者的临床资料相关,包括所采用的治疗方案和患者的预后。根据目前WHO的分类,这组蛋白3k27改变的DMG明确队列显示出该实体的典型分子改变,在特定亚组中频率存在差异。肿瘤中TP53突变的存在和MAPK通路改变的缺失与较差的预后相关。在相当比例的患者中,基因改变可以作为潜在治疗方法的目标。这个大型的、国际性的、前瞻性的DMG队列结合了肿瘤的全面分子特征和登记水平的临床数据,从而有助于更好地理解潜在的肿瘤生物学、潜在的预后和预测标志物以及靶向治疗的潜在影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Neuropathologica
Acta Neuropathologica 医学-病理学
CiteScore
23.70
自引率
3.90%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Acta Neuropathologica publishes top-quality papers on the pathology of neurological diseases and experimental studies on molecular and cellular mechanisms using in vitro and in vivo models, ideally validated by analysis of human tissues. The journal accepts Original Papers, Review Articles, Case Reports, and Scientific Correspondence (Letters). Manuscripts must adhere to ethical standards, including review by appropriate ethics committees for human studies and compliance with principles of laboratory animal care for animal experiments. Failure to comply may result in rejection of the manuscript, and authors are responsible for ensuring accuracy and adherence to these requirements.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信